Guidance For Cannabis Science Brand Products To Be Released October 2011 In Colorado Based On Accumulating Anecdotal Reports Of Successful Cancer Treatments With Cannabis Extracts.
Cannabis Science, Inc. (OTCBB: CBIS), a pioneering US biotech company developing pharmaceutical cannabis products, is pleased to announce shareholder guidance on the upcoming release of the first Cannabis Science brand of products. Cannabis extract-based products will initially be made available to licensed medical marijuana patients in Colorado. The Company is excited to announce that its proprietary brand of pharmaceutical products is nearing commercialization.
It is expected that in October 2011, Cannabis Science will contract the production and manufacturing of its branded products for distribution and sale through selected Colorado State licensed dispensaries. The first products will address the needs of patients choosing to use concentrated cannabis extracts to treat their ailments. For example, Cannabis Science has frequently been contacted by cancer patients seeking extract-based formulations for topical or internal use. Cannabis Science is responding to these patient requests for quality products. In the very near future, Cannabis Science will announce details of availability.
In light of the accumulating anecdotal reports of the successful cancer treatments with cannabis extracts, the Company will continue to keep patients updated on current peer-reviewed scientific literature supporting the historical and modern use of cannabis to treat “tumors”. Unlike conventional methods, cannabis medicines have an outstanding safety profile allowing patients in states with medical marijuana laws to safely make informed decisions to legally self-administration of various cannabis-based preparations.
Dr. Robert Melamede Ph.D., Cannabis Science president & CEO, stated, “Based on our continued commitment to educate people about the medical value of cannabis, and increasing shareholder value with revenues, releasing these products is a natural progression for us as the world has it’s cannabis awakening. Cannabis Science believes everyone has the right to fair and equal access to cannabis-based treatments worldwide.
We believe marijuana prohibition is unconstitutional. It denies people Life, Liberty and the pursuit of Happiness. Additionally, furthermore, the current legal status violates the equal protection clause. People have legal access to cannabis-based medicines in some states, while others are criminal for using their medicine. Cannabis Science will remedy this situation through educating the masses and by taking our cannabis-based products through the FDA process for nationwide distribution. Eventually, all Americans will have access to a safe and effective FDA approved medicine regardless of which state they live in. To maintain that marijuana is a dangerous, addictive drug with no medical value is scientifically absurd. Cannabis medicines, with no effective lethal dose, are far safer than aspirin, acetaminophen, and most other OTC drugs that kill thousands of Americans every year.
About Cannabis Science, Inc.
Cannabis Science, Inc. is at the forefront of pharmaceutical grade medical marijuana research and development. The Company works with world authorities on phytocannabinoid science targeting critical illnesses, and adheres to scientific methodologies to develop, produce and commercialize phytocannabinoid-based pharmaceutical products. In sum, we are dedicated to the creation of cannabis-based medicines, both with and without psychoactive properties, to treat disease and the symptoms of disease, as well as for general health maintenance.
Forward Looking Statements
This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing works such as “anticipate,” “seek,” intend,” “believe,” “plan,” “estimate,” “expect,” “project,” “plan,” or similar phrases may be deemed “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company’s reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc. does not undertake any duty nor does it intend to update the results of these forward-looking statements.